For research use only. Not for therapeutic Use.
SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs[1][2].
SW157765-sensitive NSCLC cell lines are also selectively sensitive to glucose deprivation and to GLUT8 depletion. SW157765 selectively inhibits fluorescent 2-deoxyglucose (2DG) uptake in SW157765-sensitive cells in a dose-dependent manner[1].
| Catalog Number | I044454 |
| CAS Number | 332063-87-3 |
| Synonyms | (E)-3-(furan-2-yl)-N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)prop-2-enamide |
| Molecular Formula | C19H13N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H13N3O3/c23-18(6-4-15-2-1-11-24-15)21-14-3-5-17-16(12-14)22-19(25-17)13-7-9-20-10-8-13/h1-12H,(H,21,23)/b6-4+ |
| InChIKey | QSSYRORXXFTVFI-GQCTYLIASA-N |
| SMILES | C1=COC(=C1)C=CC(=O)NC2=CC3=C(C=C2)OC(=N3)C4=CC=NC=C4 |
| Reference | [1]. Pine SR, et al. Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Transl Lung Cancer Res. 2018;7(Suppl 3):S265-S269. [2]. McMillan EA, et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell. 2018;173(4):864-878.e29. |
